FDA approves Libtayo as first immunotherapy indicated for patients with advanced basal cell carcinoma – Sanofi
The FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) from Sanofi as the first immunotherapy indicated for patients with advanced basal cell carcinoma (BCC) previously treated with a… read more.
